Sarepta Therapeutics Inc
SRPT
ISIN null / Valor 19028527
Sarepta Therapeutics Inc
UMushroom community rating:
About company
Sarepta Therapeutics Inc. is a global biotechnology firm focused on developing precision genetic medicines for rare diseases. The company leverages cutting-edge science in gene therapy, RNA technologies, and gene editing to address conditions that have limited treatment options. Sarepta's approach is characterized by its urgency to develop therapies that can significantly alter the course of diseases by targeting their genetic roots. With a portfolio that spans several advanced platforms, the company aims to provide transformative treatments in areas of high unmet medical need. Sarepta's commitment to innovation in genetic medicine positions it as a key player in the biotech industry, striving to offer hope and tangible solutions to patients facing life-altering diagnoses.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (23.09.2025):
Sarepta Therapeutics Inc reported strong financial performance in the second quarter of 2025, achieving a 42% increase in net product revenues compared to the same period last year. Additionally, the company resumed ELEVIDYS shipments for ambulatory Duchenne patients and is on track to realize significant cost savings through its ongoing restructuring efforts.
Revenue Growth
Net product revenues for Q2 2025 reached $513.1 million, marking a 42% increase year-over-year.
Profitability
The company reported a GAAP net income of $196.9 million and a non-GAAP net income of $215.2 million for the quarter, reflecting robust financial health.
Cash Position
Cash, cash equivalents, and investments increased by $202.8 million from the previous quarter, totaling $850.3 million as of Q2 2025.
Strategic Restructuring
Sarepta is advancing its restructuring plan, aimed at saving over $100 million by the end of 2025 through enhanced operational efficiencies and adjusted manufacturing commitments.
ELEVIDYS Shipments Resumed
Following FDA approval, Sarepta has resumed ELEVIDYS shipments for ambulatory individuals with Duchenne muscular dystrophy and is working on safety measures for non-ambulatory patients.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2200 M
Market cap (USD)
4,474,628
Daily traded volume (Shares)
121.49 / 119.465
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
